In a few years, all the investments Bayer has made in gene-finding companies such as Curagen (nasdaq: CRGN - news - people ) could lead to promising new drugs.
Genset (nasdaq: GENXY - news - people), Lexicon Genetics (nasdaq: LEXG - news - people) and Curagen (nasdaq: CRGN - news - people) have all announced being at various stages of obesity-drug development.
And it's especially true that Cipro is a household name in the U.S. Bayer has also spent hundreds of millions buying research from biotechs like Millennium (nasdaq: MLNM - news - people), Curagen (nasdaq: CRGN - news - people), and Lion Bioscience (nasdaq: LEON - news - people).